Pharmafile Logo
Pharmafocus logo
Advanced Search

amyotrophic lateral sclerosis

Showing 4 posts of 4 posts found.

biohaven_enrolls_first_patient_in-97b6e9e792e571e7c1572873932fc7c0

FDA knocks back Biohaven’s ALS drug over manufacturing concerns

July 22, 2019
Sales and Marketing Biohaven, FDA, Nurtec, amyotrophic lateral sclerosis, pharma

Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …

News
shutterstock_159488225

Astellas and Cytokinetics’ reldesemtiv falls short at Phase 2 in ALS

May 7, 2019
Manufacturing and Production, Sales and Marketing Astellas, als, amyotrophic lateral sclerosis, cytokinetics, pharma

Cytokinetics has announced at the American Academy of Neurology (AAN) that its fast skeletal muscle troponin activator (FSTA) reldesemtiv fell …

News
shutterstock_138095450

Aquinnah Pharmaceuticals receives $3.4 million grant to advance ALS therapies

June 21, 2018
Research and Development, Sales and Marketing Aquinnah Pharmaceuticals, als, amyotrophic lateral sclerosis, pharma

Aquinnah Pharmaceuticals has announced that it has been awarded a $3.4 million grant from the National Institute of Neurological Disorders …

News

Biogen Idec buys neurodegenerative disease rights

December 21, 2010
Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases

Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024